192 results about "Bone marrow suppression" patented technology

The invention discloses application of dihydromyricetin in preparing a medicine for preventing and treating untoward reactions in radiotherapy and chemotherapy of tumor. In particular, the application is to prepare medicines for preventing and treating untoward reactions in radiotherapy and chemotherapy of tumor, preventing and treating arrest of bone marrow and baldness, resisting mutation, preventing and treating the generation of secondary tumors, preventing and treating tumor transfer, and preventing and treating breast cancer, cervical carcinoma, intestinal cancer and the like. The invention creatively finds that the dihydromyricetin has the effects of removing free radicals, inhibiting reaction chains of the free radicals, resisting the mutation, inhibiting the expression of the tumor gene, causing the death of tumor cells, preventing and treating the tumor generation, preventing and treating the secondary tumors and the transfer of the secondary tumors and preventing and treating infection. Therefore, as the medicine for preventing and treating untoward reactions in radiotherapy and chemotherapy of tumor, the dihydromyricetin can inhibit and alleviate chemical damage, prevent and treat damage of a mutagen and further prevent gene mutation or the secondary tumors; and by combination with the radiotherapy and chemotherapy, the effects of preventing untoward reactions in radiotherapy and chemotherapy of tumor and preventing generation of tumors are achieved.

The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

The invention discloses a food therapy preparation for resisting the suppression of bone marrow after lung cancer chemotherapy. The food therapy preparation is prepared from the following components according to parts by weight: 20-30 parts of astragalus root, 10-15 parts of radix codonopsis pilosulae, 10-15 parts of angelica, 10-20 parts of glossy privet fruit, 10-20 parts of Chinese wolfberry, 20-30 parts of spatholobus stem, 6-9 parts of villous anomum, 6-10 parts of tangerine peel and 100-200 parts of crucian. By the clinical application of many years, the total effective rate of the invention is 96.29%, the acting rate is 81.48%, the effective rate is 14.81%, and the invention has safety and high efficiency. The invention is a pure traditional Chinese medicine food therapy formula, has convenient taking and no toxic or side effect and has the advantages of small toxic or side effect, good curative effect, low cost and the like.

The invention provides a novel application of a fullerene and/or metallic fullerene micro-nano material. The novel application is that of the fullerene and/or metallic fullerene micro-nano material in the preparation of drugs or drug carriers having at least one property as in 1) to 5): 1), preventing and/or treating bone marrow suppression; 2), clearing free radicals; 3), enriching bone marrow; 4), preventing and/or treating at least one of leukocyte decrease, platelet decrease, hemoglobin decrease and monocyte decrease caused by bone marrow suppression; 5), protecting bone marrow cells and/or hematopoietic cells. The fullerene and/or metallic fullerene micro-nano material is simple and quick to prepare, is good in biocompatibility and highly rich in bone marrow area, has certain residence time, can also be finally discharged out of the body by metabolism, has no evident cytotoxicity on bone marrow cells and normal cells and is safe and nontoxic. The fullerene and/or metallic fullerene micro-nano material has a promising application prospect as a protectant for bone marrow suppression caused by chemotherapy.

The invention discloses a fullerene micro-nano material with effects of prevention and/or treatment on myelosuppression and a use thereof. The novel use of the fullerene micro-nano material comprises use of the fullerene and/or metallofullerene micro-nano material in a drug or a drug carrier with at least one of properties such as 1, prevention and/or treatment on myelosuppression, 2, prevention and/or treatment on at least one of myelosuppression-caused leucopenia, platelet decreasing, hemoglobin decreasing and monocyte decreasing, and 3, protection of liver tissue, spleen tissue and kidney tissue. The myelosuppression is caused through tumor radiation therapy or rays producing myelosuppression side effects. The fullerene and/or metallofullerene micro-nano material can prevent and treat myelosuppression and prevent liver, spleen and kidney damage.

The invention relates to an application of dimethyldiguanide in drugs taking protective effect on chemoradiotherapy injury. As an optimal implementation scheme, the invention relates to the application of the dimethyldiguanide in preparing drugs taking protective effect on long-term bone marrow suppression caused by radiotherapy. As an optimal implementation scheme, the invention relates to the application of the dimethyldiguanide in preparing drugs taking protective effect on the long-term bone marrow suppression caused by chemotherapeutics. Proved by the invention, the dimethyldiguanide has a certain protective effect on hematopoietic immune cell injury caused by irradiation and/or the chemotherapeutics.

Novel compounds, compositions and methods comprising modified antibodies are provided. In preferred embodiments the disclosed modified antibodies comprise antibodies having one or more of the constant region domains altered or deleted to afford beneficial physiological properties such as enhanced target localization and rapid blood clearance. The disclosed compounds are particularly useful for the treatment of neoplastic disorders in myelosuppressed patients.

The invention provides a pharmaceutical composition for treating thrombocytopenia, which comprises gen-seng, epimeddium, radix astragali, angelica sinensis, radix rehmanniae preparata, spatholobus stems, hairyvein agrimony, and tangerine peel. The pharmaceutical composition of the invention can be prepared into clinically-acceptable dosage forms by adding routine auxiliary materials according to routine technology. The pharmaceutical composition of the invention has significant effect on treating thrombocytopenia and leucopenia, promoting proliferation of bone marrow hematopoietic stem cells, repairing damage and injury of bone marrow hematopoietic tissue caused by radiation, preventing marrow inhibition caused by radiotherapy and chemotherapy, or improving symptoms and increasing life quality of tumor patients, and has no side effect.

The invention relates to a dammarane aglycon compound and application thereof, in particular to application of oral administration and injection preparations which are prepared by a single dammarane aglycon compound prepared by basic hydrolysis by utilizing the particular patent technology of the Pegasus Pharmaceuticals Group of Canada by adopting Asian ginseng stem and leave saponin or prepared in the way that the dammarane aglycon compound is matched with other medically permissive auxiliary materials in prevention and treatment on bone marrow suppression caused by different chemotherapy and radiotherapy.

The invention provides, in part, compositions and methods for protecting a hemopoietic cell, or for treating myelosuppression, in a subject in need thereof, by administering an effective amount of an inhibitor of a SH2-containing inositol-5′-phosphatase.

The invention relates to novel medical application of anhydroicaritin, particularly to application of anhydroicaritin in preparing a drug for treating or preventing thrombopenia, and belongs to the field of medicines. In order to overcome the technical defects that, in the prior art, the thrombopenia therapeutic drug is unabiding in therapeutic effect, high in possibility of recidivation during drug discontinuance and high in side effect, the invention provides a therapeutic drug containing anhydroicaritin. The therapeutic drug can greatly improve the platelet level of a parent when being used for treating thrombopenia, particularly immune thrombopenia, and has an obvious therapeutic effect; the therapeutic drug further has the obvious therapeutic effect on treating thrombopenia caused by myelosuppression; when being used for treating thrombopenia, anhydroicaritin has the advantages of being obvious in curative effect, low in treatment cost and little in toxic and side effects, and the therapeutic drug is quite suitable for clinical popularization and application.

The invention discloses an anti-tumor compound extracted from a house lizard, as well as a preparation method of the anti-tumor compound extracted from the house lizard and application of the compound as antitumor drugs. In clinical application, the anti-tumor compound extracted from the house lizard can be dissolved with normal saline and then used in an injection way or can be prepared into preparation for oral use directly; the anti-tumor compound extracted from the house lizard can be used for the chemotherapy of gastric cancer, lung cancer, liver cancer, colon cancer, breast cancer, leucocythemia, genital system tumors, and other common malignant tumors, plays remarkable anti-tumor effect without bone marrow suppression or damage to important organs under conventional dosage; and in addition, since the anti-tumor compound extracted from the house lizard can increase T cellular immunity, the anti-tumor compound has good Aids resistance.

The invention discloses a micro-nano material for preventing and/or treating myelosuppression and application thereof. A fullerene and/or metal fullerene micro-nano material can be applied to preparing medicine with at least one of the following properties of preventing and/or treating myelosuppression, removing free radicals, preventing and/or treating at least one of leukocyte reduction, platelet reduction, hemoglobin reduction and monocyte reduction caused by myelosuppression, preventing bone marrow cells and/or hematopoietic cells, improving the function of antioxidant systems of organisms and protecting liver tissue, spleen tissue and kidney tissue. The fullerene and/or metal fullerene micro-nano material can be metabolized out of organisms, is enriched in visceral organs and marrow through blood circulation after intragastric administration or intraperitoneal injection, has an excellent function of preventing myelosuppression induced by chemotherapy in bodies, can effectively reduce toxic and side effects of chemotherapy on marrow and other organs, and is still obvious in protection effect after multiple treatment courses.

The invention discloses a Chinese medicinal composition for raising leucocytes, which is mainly prepared from the following raw material medicaments in part by weight: 6 to 60 parts of astragalus, 6 to 60 parts of Siberian solomonseal rhizome, 6 to 60 parts of Mongolian snakegourd root and 3 to 30 parts of epimedium herb. The invention also discloses a method for preparing the Chinese medicinal composition and application thereof in preparation of a medicament for treating leucopenia, improving immune function of an organism, promoting proliferation of marrow hematopoietic stem/progenitor cells, protecting hemopoietic microenvironment, repairing the damage and harm to marrow hematopoietic tissues by radioactive rays, preventing and controlling marrow suppression of chemoradiotherapy, promoting colony formation of granulocytes and monocytes, improving Chinese medicinal symptoms and living quality of patients with cancer, or promoting the recovery of patients with Qi-Yin deficiency.

Medium-chain length fatty alcohols such as octanol, decanol, dodecanol, or analogues thereof can be used as a stimulator of hematopoiesis, hematopoietic stem cell proliferation, and/or proliferation of one or more of the progenitors of red or white blood cells (e.g., erythrocyte, leukocyte, neutrophil, granulocyte, megakaryocyte, or any combination thereof). It also relates to the treatment of myelosuppression; in particular, this includes the treatment of anemia and/or neutropenia associated with chemotherapy and/or radiotherapy. Moreover, anemia arising from chronic renal failure or treatment of HIV-infected patients with AZT (zidovudine), or other inhibitors of reverse transcriptase, can be treated. Furthermore, neutropenia arising from infections, hematologic diseases, or nutritional deficiencies can be treated. It also relates to reducing drug toxicity and enhancing drug efficiency.

The invention discloses a medicinal composition for treating cancer. At present, when the cancer and malignant tumor are treated, surgical operation and radiotherapy and chemotherapy are matched for the treatment. The radiotherapy and the chemotherapy can kill cancer cells, but during the treatment, normal tissue cells are damaged, gastrointestinal reaction, bone marrow suppression and hepatorenal and cardiac function damage are induced, the bodies of patients are more weakened and the further treatment hardly can be performed, and the conventional chemical medicine treatment method cannot prevent the cancer cells from transferring and has high toxic and side effects. The invention provides a natural Chinese herbal medicinal composition for treating cancer, which consists of dark plum fruit, white paeony root, dry vine root, twotooth achyranthes root, the tail part of Chinese angelica, cortex acanthopanacis, great burdock achene and the like. A pharmacological experiment proves that: the medicinal composition can remarkably inhibit the growth of mice hepatoma H22, does not remarkably change the weight of the mice and has the obvious effect on and low toxicity to the growth of a mice transplantation hepatoma H22 cell strain.